DIA Value, Access, and Regulatory Conference 2018

pharmafile | September 4, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing dia, event, pharma 

Dr Solange Corriol-Rohou, Senior Director, Global Regulatory Affairs & Policy, Europe, at AstraZeneca Global Medicines Development, discusses DIA’s upcoming Value, Access and Regulatory Strategy event, and the value it offers to those attending the event in Hounslow from 9-10 October.

What makes the DIA Value, Access, and Regulatory Strategy 2018 Conference a must-attend event for professionals in this field?

This Value, Access, and Regulatory Strategy Conference will examine current hot topics and, through an open and scientific discussion, aim to optimise drug development and access to treatments. There is an urgent need to have all key players not only discuss the issues but propose solutions based on case studies and other examples. Only by involving different perspectives can we find real solutions that provide sustainable access to treatments for patients worldwide.

What is unique about DIA Value, Access, and Regulatory Strategy Conference compared to similar events?

Working with colleagues from the EU Commission/DG Sante on the programme committee has enabled DIA to design a great agenda involving key players. DIA’s Value, Access, and Regulatory Strategy Conference provides the only forum for open, interactive dialogue between policy makers, payers, HTA bodies, and other stakeholders, for discussing short-term strategies and long-term market solutions. Regulators and patient representatives will also be actively involved. This conference is a unique opportunity to explore disease interception, repurposing, the use and acceptance of real world data and digital health solutions, and other emerging critical topics.

Why is multi-stakeholder interaction and engagement crucial to enhancing access to medicines and treatments?

Even if some companies have proven better at it than others, industry has always interacted with academia and healthcare providers to help design and conduct clinical trials. More recently, however, participating regulatory and HTA bodies have paved the way for even more multi-stakeholder interaction. For example, the recently concluded IMI ADAPT SMART project explored how to manage early patient access through multi-stakeholder engagement, along with tools and methods to make such engagement more successful.

In this context, conference breakout sessions can easily be considered multi-stakeholder interaction.  These breakout sessions will explore what evidence must be generated for a medicinal product, throughout its life cycle, dependent upon the product’s objective – whether the product is developed to intercept a disease in an at-risk patent population, to prevent a disease through vaccination, or to cure a disease.

Learn more about the event here.

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content